Results 41 to 50 of about 2,876 (190)
Российский кардиологический журнал, 2011 Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension ...
J. M. Neutel +4 more
doaj
E-Journal of Chemistry, 2010 A simple, specific, accurate, precise and reproducible method has been developed and validated for the simultaneous estimation of hydrochlorothiazide and Olmesartan medoxomil in combined dosage form by UV spectrophotometric method.
A. T. Hemke +4 more
doaj +1 more source
P-67: Dose response antihypertensive efficacy of aliskiren (SPP 100), an orally active renin inhibitor [PDF]
, 2017 Aliskiren (SPP 100), an orally active renin inhibitor, has been shown to inhibit the production of angiotensin I and angiotensin II in healthy volunteers.
Barton, John +5 more
core
SEPARATION SCIENCE PLUS, Volume 8, Issue 9, September 2025.ABSTRACT A novel pipette‐tip solid‐phase extraction method was developed using a molecularly imprinted monolithic sorbent composed of poly(trimethylolpropane triacrylate‐co‐ethylene glycol dimethacrylate‐co‐methacrylic acid) for the selective extraction of N‐nitrosodimethylamine from pharmaceutical formulations.
Allyson Leandro Rodrigues dos Santos +2 more
wiley +1 more source
Olmesartan medoxomil: current status of its use in monotherapy
Vascular Health and Risk Management, 2006 Hans R BrunnerLausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, SwitzerlandAbstract: Olmesartan medoxomil is an angiotensin II receptor antagonist.
Hans R Brunner
doaj
Using electronic health records to support clinical trials: a report on stakeholder engagement for EHR4CR [PDF]
, 2015 Background. The conduct of clinical trials is increasingly challenging due to greater complexity and governance requirements as well as difficulties with recruitment and retention.
Dugas, Martin +7 more
core +6 more sources
The Journal of Clinical Hypertension, Volume 27, Issue 9, September 2025.ABSTRACT This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended‐release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). Patients were randomized to two groups.
Mingming Wang +11 more
wiley +1 more source
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
Vascular Health and Risk Management, 2006 Mark GreathouseSouth Hills Cardiology Associates of Pittsburgh, Pittsburgh, PA, USAAbstract: In most patients with hypertension, especially Stage 2 hypertension, adequate control of blood pressure (BP) is only achieved with combination drug therapy. When
Mark Greathouse
doaj
Rheumatology &Autoimmunity, Volume 5, Issue 1, Page 37-49, March 2025.A network meta‐analysis was carried out to identify the most recommended therapeutic schedule for patients with diabetic kidney disease. The study finally included 87 randomized‐controlled trials, including 16 different treatments and 10,485 patients.
Jiarong Liu, Jixiong Xu
wiley +1 more source
Кардиоваскулярная терапия и профилактика, 2012 Cardiovascular (CV) disease is a major factor in mortality rates around the world and contributes to more than one-third of deaths in the US. The underlying cause of CV disease is atherosclerosis, a chronic inflammatory process that is clinically ...
R. P. Mason
doaj +1 more source